OTSUKA AMERICA PHARMACEUTICAL COB SIGNED.PDF

,‘EGE1VED
NOV 2 8 2018
mAnicc PA co UNTY
REQUEST FOR EXECUTION OF DOCUMENTLERK BOARD or UERV!S
OflS
'
TO: Fran McCarroll, Clerk of the Board
Board of Supervisors
Tenth Floor, Administration Building
DATE: 11/27/18 C# C-26-18-007-3-00, C-26-18-008-3-00, C-26-18-009-3-00
Correctional Health Services
Submitting Department:
Outpatient Sample Program for Long Acting Injectable Antipsychotic Medications
Title of Document:
Date of Legal Review: 11/21/18 Date of Board Approval: 6/27/18
Copy of Agenda Item Attached (AlF)
Original Enclosed for Official Filing
3
Number of copies enclosed
(Include desired number of copies in addition to the original which is retained for the official files.)
Carolynn Morris
Return Copies to:
234 N. Central Suite 5000
Location/Address
Phoenix, AZ 85004
Date Executed and Returned:

(9IA
Agenda Item Id:
Item Title
AGREEMENT FOR OUTPATIENT SAMPLE PROGRAM WITH 01 -cl IKA AMERICA PHARMACEUTICAL, INC
C Number: C-26-18-007-3-00
Action Requested:
Adopt a Resolution which authorizes an Agreement between Otsuka America Pharmaceutical, Inc. and
Maricopa County through the Department of Correctional Health Services, for the purpose of a free
medication for psychiatric patients. Approve and authorize, by Resolution, Ma ricopa County by and
through its Department of Correctional Health Services (MCDCHS), to process a non-financial Outpatient
Sample Program (OSP) form (ONRHA052A 32176004) with Otsuka America Pharmaceutical, Inc., for free
samples of ABILIFY MAINTENA (APRIPIPRAZOLE) for extended-release injectable suspension. This
Agreement is non-financial and is effective from June 27, 2018 until June 27, 2023.
Board Required Information:
Long acting injectable (LAI) antipsychotic medications are used frequently in the community for
psychiatric conditions, including schizophrenia, schizoaffective disorder, and bipolar disorder.
Given the large number of jail inmates with psychiatric conditions who get treated with LAI medications
in the community, best practices dictate that these medications be continued in jail for patients who are
stable and compliant on LAls.
The cost of LAIs is significant. On average, 200 patients per month are receiving injectable antipsychotic
medications in Maricopa County Jails. This comprises 20% of the monthly pharmacy budget for a jail
population of 7500.
Fortunately, pharmaceutical companies understand the burden that LAIs have on county budgets and
have programs designed specifically to provide medications, free of charge, to incarcerated populations.
Creating a partnership with these companies will allow for continuity of care on patients, while in jail,
who are stable and compliant in the community with LAI medications.
It will also allow for 'new starts' on patients who are good candidates (either those who have been on
LAIs in the past, or who may benefit from doing a trial of LAIs for the first time).
Additional Information:
Recent medical literature indicates that adherence to antipsychotic medications may lead to a decrease
in criminal recidivism.

RESOLUTION: C-26-18-007-3-00
OUTPATIENT SAMPLE PROGRAM WITH OTSUKA AMERICA PHARMACEUTICAL, INC.
LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS
WHEREAS, an average of 200 inmate patients per month receive long acting injectable antipsychotic
("LAI") medications comprising of 20% of the monthly pharmacy budget for a jail population of 7500;
WHEREAS, recent medical literature indicates that adherence to antipsychotic medication may lead to a
decrease in criminal recidivism, and where patients are carefully selected for LAI treatment, in
combination with discharge planning and "warm handoffs," there is the potential of decreasing the
recidivism of this vulnerable patient population;
WHEREAS, partnering with pharmaceutical companies to receive LAI medications free-of-charge,
Maricopa County Correctional Health Services will be able to continue these treatments on stable patients
and to initiate therapy on candidates who may benefit the most;
NOW THEREFORE:
BE IT RESOLVED that the Board of Supervisors hereby adopts Resolution: C-26-18-007-3-00 and
authorizes Maricopa County by and through its Department of Correctional Health Services (MCDCHS),
to process a non-financial Outpatient Sample Program (OSP) form (ONRHA052A 32176004) with Otsuka
America Pharmaceutical, Inc., for free samples of ABILIFY MAINTENA® (APRIPIPRAZOLE) for extended-
release injectable suspension.
Dated this dile\ day of dkiav-AXA('‘ , 2018.
IN WITNESS WHEREOF, the parties agree to enter into this agreement:
APPROVED AS TO FORM: FOR AND ON BEHALF OF
MARICOPA COUNTY
By
Chairman, Board of Sup-ervisors
Date NOV 2 8 '28
Date
ATTEST:
LOC-Di V-6,--r1e,- CA-k3 •Creiek of the Board bk09-1q
NOV 2 8 in
Date

RESOLUTION: C-26-18-007-3-00
OUTPATIENT SAMPLE PROGRAM WITH OTSUKA AMERICA PHARMACEUTICAL, INC.
LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS
WHEREAS, an average of 200 inmate patients per month receive long acting injectable antipsychotic
("LAI") medications comprising of 20% of the monthly pharmacy budget for a jail population of 7500;
WHEREAS, recent medical literature indicates that adherence to antipsychotic medication may lead to a
decrease in criminal recidivism, and where patients are carefully selected for LAI treatment, in
combination with discharge planning and "warm handoffs," there is the potential of decreasing the
recidivism of this vulnerable patient population;
WHEREAS, partnering with pharmaceutical companies to receive LAI medications free-of-charge,
Maricopa County Correctional Health Services will be able to continue these treatments on stable patients
and to initiate therapy on candidates who may benefit the most;
NOW THEREFORE:
BE IT RESOLVED that the Board of Supervisors hereby adopts Resolution: C-26-18-007-3-00 and
authorizes Maricopa County by and through its Department of Correctional Health Services (MCDCHS),
to process a non-financial Outpatient Sample Program (OSP) form (ONRHA052A 32176004) with Otsuka
America Pharmaceutical, Inc., for free samples of ABILIFY MAINTENA® (APRIPIPRAZOLE) for extended-
release injectable suspension.
Dated this dgfk day of )10/Mlar/te , 2018.
IN WITNESS WHEREOF, the parties agree to enter into this agreement:
APPROVED AS TO FORM: FOR AND ON BEHALF OF
MARICOPA COUNTY —
I
By
Chairman, Board of Soperyisors
Date NOV (2
Date
ATTEST:
1-AtetA cect__-"bi V-a-T012-- Ci-t) Cleik of the Board 0 102\\-%
//4203 NOV 2 8
Date